MiR-183-5p Promotes Migration and Invasion of Prostate Cancer by Targeting TET1

Author:

Feng Yuehua1,Wang Kai2,Qin Minchao1,Zhuang Qianfeng1,Chen Zhen1

Affiliation:

1. The Third Affiliated Hospital of Soochow University

2. The Affiliated Sir Run Run Hospital of Nanjing Medical University

Abstract

Abstract Background: Prostate cancer (PCa) is one of the common malignant tumors and it is difficult to diagnose at its early stage. MiR-183-5p has been reported involved in the proliferation of human PCa, this study aimed to investigate how miR-183-5p affects the migration and invasion of prostate cancer. Methods: In this study, we analyzed the expression of miR-183-5p in PCa patients and its correlation with clinicopathological parameters based on TCGA data portal. CCK-8, migration assay and invasion and wound-healing assay were performed to detect proliferation, migration and invasion in PCa cells. Results:We found the expression of miR-183-5p was significantly increased in PCa tissues, and high expression of miR-183 was positively associated with poor prognosis of PCa patients. Over-expression of miR-183-5p promoted the migration, invasion capacities of PCa cells, whereas knockdown of miR-183-5p showed reversed function. Furthermore, luciferase reporter assay showed TET1 was identified as a direct target of miR-183-5p, which was negatively correlation with miR-183-5p expression level. Importantly, rescue experiments demonstrated TET1 over-expression could reverse miR-183-5p mimic induced-acceleration of PCa malignant progression. Conclusion:Our results indicated that miR-183-5p could act as a tumor promoter in PCa and it accelerated the malignant progression of PCa by directly targeting and down-regulating TET1.

Publisher

Research Square Platform LLC

Reference43 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;Cancer J Clin,2018

2. Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis;Birnbaum MD;Oncogene,2019

3. Pan J, Zhao J, Ni X, Gan H, Wei Y, Wu J, Zhang T, Wang Q, Stephen JF, Wang B et al. The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer.Molecular oncology2022.

4. ESTAT3 Inhibitor AG-490 Inhibits the Growth of Prostate Cancer by miR-503-5p Both In Vivo and In Vitro;Tan G;Technol Cancer Res Treat,2020

5. LncRNA MCM3AP-AS1 Promotes Cell Proliferation and Invasion Through Regulating miR-543-3p/SLC39A10/PTEN Axis in Prostate Cancer;Jia Z;OncoTargets and therapy,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3